Microcystic Lymphatic Malformation
2
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Palvella TherapeuticsWAYNE, PA
2 programs1
1
QTORIN 3.9% Rapamycin Anhydrous GelPhase 31 trial
PTX-022Phase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
Palvella TherapeuticsQTORIN 3.9% Rapamycin Anhydrous Gel
Palvella TherapeuticsPTX-022
Clinical Trials (2)
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Start: Jul 2024Est. completion: Jul 2026
Phase 3Recruiting
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
Start: Jan 2022Est. completion: Dec 2022
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
1 companies competing in this space